Articles Tagged With:
-
Ethicists Make Changes to Improve Consult Documentation
When clinical ethicists provide guidance to resolve a healthcare ethics question, they are making recommendations about a patient’s clinical care. A Veterans Health Administration National Center for Ethics in Health Care Improvement Team set out to make ethics documentation easier, while still maintaining high quality standards.
-
Ethicists Expand Footprint with Bioethics Ambassador Program
As Memorial Sloan Kettering (MSK) Cancer Center grew from a single campus in Manhattan to more than 12 outpatient care centers throughout New York City and the surrounding suburbs, ethicists saw the need for an expanded presence. To create a cadre of local clinicians with knowledge in addressing common ethical issues that arise in cancer care, the MSK Ethics Committee created a Bioethics Ambassador Program.
-
Ethicists Are Finding Ways to Assist in Outpatient Settings
As hospitals continue to merge and expand their geographic footprint, ethicists must meet the needs of clinicians at all those care settings.
-
New Data on Brain-Injured Patients Are ‘Wake-Up Call’ for Clinical Ethicists
Some ethics consultations involve brain-injured patients who are unresponsive, and contain discussions center around withdrawing life-sustaining interventions. At least for some of those patients, there may be more hope for recovery than previously was believed to be the case, a recent study suggests.
-
How Does Your Ethics Program Compare? New Ways to Obtain Benchmarking Data
To improve, ethics programs need to know how they compare to other ethics programs. However, a lack of benchmarking data in the bioethics field remains a frustrating obstacle.
-
Cardioprotective Therapy Initiation in Chemotherapy Patients
An international study of patients undergoing cancer chemotherapy or left chest radiation therapy showed that those who showed isolated reductions in echocardiography left ventricular global longitudinal strain but not ejection fraction during follow-up who were randomized to neurohormonal therapy vs. usual care showed better preservation of 12-month cardiac magnetic resonance-determined ejection fraction.
-
Prognostic Value of Stress Echocardiography
A UK National Health Service database study of stress echocardiography has shown the degree of ischemia accurately predicts the risk of future cardiovascular events over five years. The same study also showed that a negative test in patients without a history of cardiac disease identifies patients with no more than the expected background risk of an event for patients in this demographic for five years.
-
EARLY TAVR Study Reports a Win for TAVR in Asymptomatic Severe AS
In this multicenter, randomized trial comparing transcatheter aortic valve replacement (TAVR) with active surveillance in patients with asymptomatic severe aortic stenosis (AS), early TAVR showed an advantage regarding the composite endpoint of death, stroke, or unplanned hospitalization for cardiovascular causes. This result was driven primarily from the progression to severe symptomatic AS among the surveillance group, with no significant difference in mortality.
-
Cardiac and Paracardiac Structure in the SUMMIT Trial
A cardiac magnetic resonance imaging study in a subgroup of the patients in the SUMMIT trial of tirzepatide in patients with heart failure with preserved ejection fraction has demonstrated that patients treated with tirzepatide had reduced left ventricular mass and paracardiac adipose tissue compared to placebo-treated patients, which may partially explain the reduction in heart failure events observed in the main SUMMIT trial.
-
A New Treatment for Heart Failure with Preserved Ejection Fraction
A recent randomized, placebo-controlled trial of the long-acting glucagon-like peptide-1 receptor agonist tirzepatide in patients with heart failure with preserved left ventricular ejection fraction who have obesity, diabetes, and one other weight-related comorbidity has shown that tirzepatide not only reduces the symptoms of heart failure, but reduces the incidence of worsening heart failure events.